AU2015334469B2 - Permanent epigenetic gene silencing - Google Patents

Permanent epigenetic gene silencing Download PDF

Info

Publication number
AU2015334469B2
AU2015334469B2 AU2015334469A AU2015334469A AU2015334469B2 AU 2015334469 B2 AU2015334469 B2 AU 2015334469B2 AU 2015334469 A AU2015334469 A AU 2015334469A AU 2015334469 A AU2015334469 A AU 2015334469A AU 2015334469 B2 AU2015334469 B2 AU 2015334469B2
Authority
AU
Australia
Prior art keywords
domain
dna
binding
atr
atrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015334469A
Other languages
English (en)
Other versions
AU2015334469A1 (en
Inventor
Angelo AMABILE
Angelo Leone Lombardo
Alessandro MIGLIARA
Luigi Naldini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Telethon
Ospedale San Raffaele SRL
Original Assignee
Fondazione Telethon
Ospedale San Raffaele SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015334469(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fondazione Telethon, Ospedale San Raffaele SRL filed Critical Fondazione Telethon
Publication of AU2015334469A1 publication Critical patent/AU2015334469A1/en
Application granted granted Critical
Publication of AU2015334469B2 publication Critical patent/AU2015334469B2/en
Priority to AU2022202407A priority Critical patent/AU2022202407B2/en
Priority to AU2025201007A priority patent/AU2025201007A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01037—DNA (cytosine-5-)-methyltransferase (2.1.1.37)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015334469A 2014-10-24 2015-10-23 Permanent epigenetic gene silencing Active AU2015334469B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022202407A AU2022202407B2 (en) 2014-10-24 2022-04-12 Permanent epigenetic gene silencing
AU2025201007A AU2025201007A1 (en) 2014-10-24 2025-02-13 Permanent epigenetic gene silencing

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1418965.8A GB201418965D0 (enExample) 2014-10-24 2014-10-24
GB1418965.8 2014-10-24
PCT/IB2015/058202 WO2016063264A1 (en) 2014-10-24 2015-10-23 Permanent epigenetic gene silencing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202407A Division AU2022202407B2 (en) 2014-10-24 2022-04-12 Permanent epigenetic gene silencing

Publications (2)

Publication Number Publication Date
AU2015334469A1 AU2015334469A1 (en) 2017-05-25
AU2015334469B2 true AU2015334469B2 (en) 2022-01-20

Family

ID=52103358

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015334469A Active AU2015334469B2 (en) 2014-10-24 2015-10-23 Permanent epigenetic gene silencing
AU2022202407A Active AU2022202407B2 (en) 2014-10-24 2022-04-12 Permanent epigenetic gene silencing
AU2025201007A Pending AU2025201007A1 (en) 2014-10-24 2025-02-13 Permanent epigenetic gene silencing

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022202407A Active AU2022202407B2 (en) 2014-10-24 2022-04-12 Permanent epigenetic gene silencing
AU2025201007A Pending AU2025201007A1 (en) 2014-10-24 2025-02-13 Permanent epigenetic gene silencing

Country Status (13)

Country Link
US (1) US12152240B2 (enExample)
EP (2) EP3995584A1 (enExample)
JP (3) JP7002936B2 (enExample)
CN (2) CN107109433B (enExample)
AU (3) AU2015334469B2 (enExample)
CA (1) CA2965591A1 (enExample)
DK (1) DK3209783T3 (enExample)
ES (1) ES2906263T3 (enExample)
GB (1) GB201418965D0 (enExample)
HU (1) HUE057846T2 (enExample)
PL (1) PL3209783T3 (enExample)
PT (1) PT3209783T (enExample)
WO (1) WO2016063264A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
GB201418965D0 (enExample) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
WO2016073955A2 (en) * 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP3273976B1 (en) * 2015-03-27 2023-07-26 President and Fellows of Harvard College Modified t cells and methods of making and using the same
US11674144B2 (en) * 2015-04-16 2023-06-13 California Institute Of Technology Fractional regulation of transcription
HK1254190A1 (zh) 2015-05-08 2019-07-12 President And Fellows Of Harvard College 通用供体干细胞和相关方法
EP3362571A4 (en) 2015-10-13 2019-07-10 Duke University GENOM ENGINEERING WITH TYPE I CRISPR SYSTEMS IN EUKARYOTIC CELLS
KR20250044471A (ko) 2015-11-30 2025-03-31 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
CN121294437A (zh) 2015-12-04 2026-01-09 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP3463484B1 (en) * 2016-05-27 2026-01-07 The Regents of the University of California Methods and compositions for targeting rna polymerases and non-coding rna biogenesis to specific loci
US20190100732A1 (en) * 2016-06-02 2019-04-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Assay for the removal of methyl-cytosine residues from dna
US12214056B2 (en) 2016-07-19 2025-02-04 Duke University Therapeutic applications of CPF1-based genome editing
CA3034369A1 (en) 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
WO2018049075A1 (en) 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
WO2018111944A1 (en) 2016-12-12 2018-06-21 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
US11873496B2 (en) 2017-01-09 2024-01-16 Whitehead Institute For Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
US20210322577A1 (en) * 2017-03-03 2021-10-21 Flagship Pioneering Innovations V, Inc. Methods and systems for modifying dna
AU2018237159A1 (en) 2017-03-22 2019-09-05 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11072782B2 (en) 2017-07-24 2021-07-27 Albert-Ludwigs-Universitaet Freiburg Construct for epigenetic modification and its use in the silencing of genes
CN107759673B (zh) * 2017-09-27 2021-06-04 复旦大学 可对hbv的dna进行表观甲基化修饰的蛋白分子及其应用
WO2019079462A1 (en) 2017-10-17 2019-04-25 President And Fellows Of Harvard College TRANSCRIPTION MODULATION SYSTEMS BASED ON CAS9
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOMIC ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES
MX2020010974A (es) 2018-04-19 2021-01-20 Univ California Composiciones y métodos para la edición de genes.
CA3099364A1 (en) 2018-05-11 2019-11-14 Crispr Therapeutics Ag Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors
CN112739817B (zh) * 2018-09-21 2025-01-24 克莱格医学有限公司 表达有嵌合受体的t细胞
GB201817821D0 (en) * 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
US12428639B2 (en) 2019-03-05 2025-09-30 Ramot At Tel-Aviv University Ltd. Plant DNA methyltransferases and uses thereof
WO2020219726A1 (en) 2019-04-23 2020-10-29 Sangamo Therapeutics, Inc. Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
US11987791B2 (en) 2019-09-23 2024-05-21 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
AU2020382017A1 (en) * 2019-11-13 2022-05-12 Crispr Therapeutics Ag Methods of manufacturing CAR-T cells
WO2021095013A1 (en) * 2019-11-13 2021-05-20 Crispr Therapeutics Ag Manufacturing process for making t cells expressing chimeric antigen receptors
KR20230074525A (ko) * 2020-09-24 2023-05-30 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 유전자 발현을 억제하기 위한 조성물 및 방법
CA3202977A1 (en) * 2020-12-22 2022-06-30 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
AU2022213505A1 (en) * 2021-02-01 2023-09-07 Epsilen Bio S.R.L. Gene silencing
CN117545844A (zh) * 2021-02-15 2024-02-09 圣拉斐尔医院有限责任公司 用于癌症治疗的表观遗传沉默
CN115247175B (zh) * 2021-11-25 2025-10-17 南京启真基因工程有限公司 构建setdb1基因突变的表观遗传失调模型猪核移植供体细胞的基因编辑系统及其应用
EP4486901A1 (en) * 2022-03-04 2025-01-08 Epigenic Therapeutics Inc. Compositions and methods of genome editing
WO2023250148A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
IL317913A (en) * 2022-06-23 2025-02-01 Chroma Medicine Inc Compositions and methods for epigenetic regulation of B2M expression
WO2023250490A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of trac expression
WO2023250512A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of ciita expression
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
CN120435557A (zh) 2022-08-19 2025-08-05 图恩疗法股份有限公司 通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
KR20250110209A (ko) * 2022-09-23 2025-07-18 엔크로마 바이오, 인크. Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법
WO2024081879A1 (en) * 2022-10-14 2024-04-18 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of cd247 expression
AU2024220624A1 (en) 2023-02-17 2025-09-11 Whitehead Institute For Biomedical Research Compositions and methods for making epigenetic modifications
WO2024220857A1 (en) * 2023-04-20 2024-10-24 Chroma Medicine, Inc. Fusion proteins for epigenetic regulation
WO2024238700A1 (en) * 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
IT202300011790A1 (it) 2023-06-08 2024-12-08 Fond Telethon Ets Protocolli di manipolazione genica in cellule immunitarie
CN119464241A (zh) * 2023-08-09 2025-02-18 厦门大学 瓜氨酸化setdb1多肽及其在诊断类风湿性关节炎中的应用
WO2025160155A1 (en) 2024-01-22 2025-07-31 The Broad Institute, Inc. Epigenetic targeting of prion diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072788A1 (en) * 2002-02-21 2003-09-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for reversibly controlling expression of target genes in cells
US20120207744A1 (en) * 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP2000517297A (ja) 1996-08-07 2000-12-26 ダーウィン・ディスカバリー・リミテッド Ｍｍｐとｔｎｆの抑制活性を有するヒドロキサム酸誘導体およびカルボン酸誘導体
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US20020188103A1 (en) 1998-10-09 2002-12-12 Timothy H. Bestor Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
CA2407460C (en) * 2000-04-28 2013-06-25 Sangamo Biosciences, Inc. Targeted modification of chromatin structure
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
WO2005028630A2 (en) 2003-09-19 2005-03-31 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US20070192880A1 (en) 2003-10-03 2007-08-16 University Of Rochester Horming response element binding transregulators
JP2008506359A (ja) 2004-04-08 2008-03-06 サンガモ バイオサイエンシズ インコーポレイテッド ジンクフィンガータンパク質による神経因性疼痛の処置
GB0526449D0 (en) 2005-12-23 2006-02-08 Medical Res Council Polypeptide targeting
KR100756055B1 (ko) 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
GB0700374D0 (en) 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
EP2727600B1 (en) 2009-07-28 2019-03-27 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for repressing a huntington gene
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
GB201121924D0 (en) 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
US10570378B2 (en) 2012-02-28 2020-02-25 Sigma-Aldrich Co. Llc Targeted histone acetylation
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
AU2013231972B2 (en) 2012-03-14 2018-03-22 Salk Institute For Biological Studies Adenoviral tumor diagnostics
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
NZ714353A (en) 2012-05-25 2017-05-26 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
DE202013012597U1 (de) 2012-10-23 2017-11-21 Toolgen, Inc. Zusammensetzung zum Spalten einer Ziel-DNA, umfassend eine für die Ziel-DNA spezifische guide-RNA und eine Cas-Protein-codierende Nukleinsäure oder ein Cas-Protein, sowie deren Verwendung
AU2013355214B2 (en) 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP2771468B1 (en) 2012-12-12 2015-02-11 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
PL2931898T3 (pl) 2012-12-12 2016-09-30 Le Cong Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
EP2898075B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
EP4286403A3 (en) 2012-12-12 2024-02-14 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR20220139433A (ko) 2012-12-17 2022-10-14 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Rna-가이드된 인간 게놈 조작
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
EP2970208A4 (en) 2013-03-15 2016-11-30 Gen Hospital Corp SPECIFICITY INCREASES FOR RNA-MEDIATED CHANGES
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
ES2987399T3 (es) 2013-06-05 2024-11-14 Univ Duke Edición génica guiada por ARN y regulación génica
SG11201600060VA (en) 2013-07-10 2016-02-26 Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
WO2015139139A1 (en) 2014-03-20 2015-09-24 UNIVERSITé LAVAL Crispr-based methods and products for increasing frataxin levels and uses thereof
EP3169702A4 (en) 2014-07-14 2018-04-18 The Regents of The University of California A protein tagging system for in vivo single molecule imaging and control of gene transcription
EP3169776B1 (en) 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
WO2016054106A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California SCAFFOLD RNAs
US10583201B2 (en) 2014-10-10 2020-03-10 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
JP6835726B2 (ja) 2015-01-28 2021-02-24 パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
WO2017015637A1 (en) 2015-07-22 2017-01-26 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
WO2017044487A1 (en) 2015-09-09 2017-03-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Genetic engineering of macrophages for immunotherapy
EP3147363B1 (en) 2015-09-26 2019-10-16 B.R.A.I.N. Ag Activation of taste receptor genes in mammalian cells using crispr-cas-9
JP6500293B2 (ja) 2015-11-25 2019-04-17 国立大学法人群馬大学 Ｄｎａメチル化編集用キットおよびｄｎａメチル化編集方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072788A1 (en) * 2002-02-21 2003-09-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for reversibly controlling expression of target genes in cells
US20120207744A1 (en) * 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ll HONGWEI ET AL, "The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells", JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, vol. 281, no. 28, pages 19489 - 19500 *

Also Published As

Publication number Publication date
CA2965591A1 (en) 2016-04-28
CN107109433A (zh) 2017-08-29
DK3209783T3 (da) 2022-02-14
WO2016063264A1 (en) 2016-04-28
JP2022068875A (ja) 2022-05-10
CN116789846A (zh) 2023-09-22
ES2906263T3 (es) 2022-04-13
GB201418965D0 (enExample) 2014-12-10
US20190032049A1 (en) 2019-01-31
EP3995584A1 (en) 2022-05-11
HUE057846T2 (hu) 2022-06-28
AU2022202407B2 (en) 2024-11-14
JP2025063201A (ja) 2025-04-15
AU2025201007A1 (en) 2025-03-06
JP2017537611A (ja) 2017-12-21
EP3209783B1 (en) 2021-11-24
EP3209783A1 (en) 2017-08-30
JP7002936B2 (ja) 2022-02-04
AU2022202407A1 (en) 2022-05-05
PL3209783T3 (pl) 2022-04-19
US12152240B2 (en) 2024-11-26
AU2015334469A1 (en) 2017-05-25
JP7623272B2 (ja) 2025-01-28
PT3209783T (pt) 2022-02-10
CN107109433B (zh) 2023-01-10

Similar Documents

Publication Publication Date Title
AU2022202407B2 (en) Permanent epigenetic gene silencing
US20240139319A1 (en) Gene silencing
US20220033856A1 (en) Methods for increasing fetal hemoglobin content in eukaryotic cells and uses thereof for the treatment of hemoglobinopathies
AU2018253958B2 (en) Gene therapy
JP7642548B2 (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
AU2019294294A1 (en) Gene therapy
US20230340471A1 (en) Permanent Epigenetic Gene Silencing
Weber et al. Editing a gglobin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype
US20250115935A1 (en) Engineered multipartite transcriptional effectors sourced from human protein domains
US20250236870A1 (en) Permanent epigenetic gene silencing
Gutiérrez-Guerrero Gene editing as an alternative to retroviral vectors for Wiskott-Aldrich syndrome gene therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)